<DOC>
	<DOC>NCT01394653</DOC>
	<brief_summary>A study to compare time-course changes of plasma concentration of YM060 orally-disintegrating tablet with those of conventional tablet. Tablets will be administered with water.</brief_summary>
	<brief_title>A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake</brief_title>
	<detailed_description />
	<mesh_term>Ramosetron</mesh_term>
	<criteria>healthy assessed by the principal investigator or subinvestigators nonsmoking or stop smoking at least 90 days before the study body weight: over 50.0kg and less than 80.0kg body mass index (BMI): over 17.6 and less than 26.4 participated in another clinical trial (including a postmarketing clinical study) within 120 days before the study donated 400mL of whole blood within 90 days, 200mL of whole blood within 30 days or blood components within 14 days before the study received any drugs within 7 days before the study or going to receive any drugs deviance from normal range in vital signs (blood pressure, pulse rate, and body temperature) or 12lead ECG deviance from normal range in labtests history of drug allergy history or current diagnosis of stomach, small intestine or large intestine diseases history or current diagnosis of inflammatory bowel disease (Crohn's disease or colitis ulcerative) history or current diagnosis of colitis ischemic history or current diagnosis of hepatic diseases history or current diagnosis of cardiovascular diseases history or current diagnosis of respiratory diseases history or current diagnosis of malignant tumor received ramosetron tablet</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>YM060</keyword>
	<keyword>ramosetron</keyword>
	<keyword>orally-disintegrating tablet</keyword>
	<keyword>OD tablet</keyword>
	<keyword>bioequivalence</keyword>
</DOC>